Compare Snap On Incorporated (SNA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap On Incorporated vs BIO-TECHNE Corp — how do they compare? Snap On Incorporated trades at $412.41 (market cap $21.27B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Snap On Incorporated is the larger of the two by market cap, and Snap On Incorporated pays the higher dividend (2.37%). Which is the better fit depends on your goals.
| SNA | TECH | |
|---|---|---|
Market Cap | $21.27B | $11.24B |
Sector | Technology | Health |
52-Week High | $419.31 | $72.29 |
52-Week Low | $321.17 | $43.31 |
Enterprise Value | $20.90B | $11.32B |
Dividend Yield | 2.37% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snap-on Incorporated (SNA) trades at $416.35, up 0.4% on the day, with a bullish technical outlook supported by moving averages and strong support near $413. The company reported Q2 2026 earnings of $4.96 per share, beating estimates, with organic sales growth of 3% driven by tools and diagnostics. Recent acquisitions like Diesel Laptops for $100 million expand its heavy-duty diagnostics reach, while solid cash flow and a 19.6% net income margin underscore operational strength.
SNA offers a compelling investment case with robust profitability, strategic growth initiatives, and a consensus price target of $455.33 implying 9.4% upside. Risks include integration costs from acquisitions, premium valuation multiples, and potential macroeconomic pressures on automotive demand. Analyst sentiment is positive with 65% buy ratings, but execution on growth initiatives remains key to justifying current valuations.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
